MWNA
ESPR

Marshall Wace North America’s Esperion Therapeutics ESPR Stock Holding History

Marshall Wace North America’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1.52M Buy
+125,953
New +$1.83M 0.01% 799
2021
Q2 		– Sell
-7,175
Closed -$201K – 1541
2021
Q1 		$201K Buy
+7,175
New +$212K ﹤0.01% 1408
2020
Q3 		– Sell
-19,763
Closed -$1.01M – 1282
2020
Q2 		$1.01M Buy
+19,763
New +$827K 0.01% 754
2020
Q1 		– Sell
-23,750
Closed -$1.42M – 1334
2019
Q4 		$1.42M Buy
+23,750
New +$1.07M 0.01% 649
2019
Q2 		– Sell
-4,091
Closed -$164K – 1274
2019
Q1 		$164K Buy
+4,091
New +$184K ﹤0.01% 1029
2013
Q4 		$201K Sell
14,615
-891
-6% -$13K ﹤0.01% 642
2013
Q3 		$292K Buy
+15,506
New +$260K 0.01% 519

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Marshall Wace North America's ESPR Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Esperion Therapeutics (ESPR) in Q3 2021: 125,953 shares worth $1.52M. The stake represents 0.01% of the portfolio and ranks #799 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in ESPR as recently as Q1 2021.

Marshall Wace North America first reported a position in ESPR in Q3 2013 and has held it in 7 quarters since. 139 funds tracked by Wall St. Rank hold ESPR as of Q3 2021.

  • Marshall Wace North America held 125,953 shares of Esperion Therapeutics worth $1.52M as of Q3 2021.
  • Esperion Therapeutics was a new Marshall Wace North America position in Q3 2021.
  • Esperion Therapeutics made up 0.01% of Marshall Wace North America's portfolio in Q3 2021, its #799 holding.
  • Marshall Wace North America first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 7 quarters since.
  • 139 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.